

Patent Application of

Corrado Spadafora,  
Clague P. Hodgson,  
Rodolfo N. Lorenzini,

For

**TITLE**

**RNA TRANSFECTION OF SPERM CELLS.**

**CROSS-REFERENCE TO RELATED APPLICATIONS**

Provisional patent application by the same title and inventors, filed in The US Patent and Trademark Office, 10/13/00.

## **Literature References:**

### **US Patent Documents**

Freeman S, Abraham G, McCune CS, Moolten FL, Koeplin D.  
Cancer therapy utilizing malignant cells expressing HSV-TK (1997), US Patent No. 5,601,818.

### **Scientific Literature**

Hogan B, Beddington R, Costantini F, Lacy E.  
Manipulating the mouse embryos: a laboratory manual. (1994) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

Jaenisch R.  
Germ line integration and mendelian transmission of the exogenous Moloney leukemia virus. (1976) *Proc. Natl. Acad. Sci. (USA)* 73: 1260-1264

Lavitrano M, Camaioni A, Fazio VM, Dolci S, Farace MG, Spadafora C.  
Sperm cells as vectors for introducing foreign DNA into eggs: genetic transformation of mice. (1989) *Cell*. 57: 717-23.

Palmiter RD, Brinster RL.  
Germ-line transformation of mice. (1986) *Annu. Rev. Genet.* 20: 465-99.

Salter D and Crittenden LB  
Artificial insertion of a dominant gene for resistance to avian leukosis virus into the germ line of the chicken. (1989) *Theor. Appl. Genet.* 77: 457-461

Hodgson CP and Solaiman F.  
Virosomes: Cationic liposomes enhance retroviral transduction. (1996) *Nature Biotechnology* 14:339-42.

Whittingham, DG, Culture of mouse ova. (1971) *J. Reprod. Fertil. Suppl.* Jun;14:7-21.

### **International Patent Documents**

Hodgson CP, Zink MA, Xu G-P. Chimeric Viral Packaging Signal without *Gag* Gene Sequences. (1998) PCT/US98/24667.

## BACKGROUND—FIELD OF INVENTION

This invention relates to methods and materials for the production and use of transgenic multi-cellular organisms in agriculture and biotechnology, as well as for gene therapy in man.

## BACKGROUND—DESCRIPTION OF THE PRIOR ART

Transgenic plants and animals result from the introduction of foreign nucleic acids into the germ line. The nucleic acids (RNA or DNA) can be introduced in the form of either a virus (such as a retrovirus), so-called transduction, or through direct introduction by physical or chemical means (transfection).

One of the first examples of germ line transduction was Jaenisch, 1976, who incubated murine retroviruses with mouse blastocysts, creating mice derived from both transgenic and non-transgenic cells (chimeric mice). The chimeric mice were then bred to produce lines of mice with unique insertions of proviruses in the germ line. Later, genetically engineered retroviral vectors were used to make transgenic mammals and avians (Salter and Crittenden, 1989).

Early examples of germ line transfection used micro-injection to introduce DNA into the male pronucleus of fertilized zygotes (Palmiter and Brinster). Other methods of transfection include: electroporation, gene gun, and chemical introduction (by lipofection, calcium phosphate, DEAE dextran, etc.)

An unusual method for introducing genes into animals by sperm transfection was first reported in 1989 by Lavitrano and Spadafora (Lavitrano *et al.*, 1989). Briefly, mouse epididymal spermatozoa were pre-incubated with pSV2CAT plasmid DNA and used in *in vitro* fertilization assays. Plasmid sequences were found in about 30% of the F<sub>0</sub> animals generated with these fertilizations and some of them expressed the CAT gene; foreign DNA sequences were further transmitted to the F<sub>1</sub> progeny when founders were bred with wild type mice.

Although a variety of methods are available for introducing genes into the germ lines of multi-cellular organisms, all share the common feature that they are somewhat technically difficult. Ideally, it would be desirable to have a method for introducing foreign genes directly into the animal in a manner that was both heritable and straightforward. It would be especially desirable if the method provided episomal transmission (as opposed to integration into the germ line), in order to preserve germ line integrity. This would be particularly useful in human gene therapy procedures, where germ line integration should be avoided.

In the instant invention, RNA is taken up by the sperm, where it is reverse-transcribed into cDNA and is faithfully expressed and transmitted to the organs and tissues of founder animals and their progeny.

## SUMMARY

In accordance with the present invention, transgenic animals may be obtained by fertilizing eggs with sperm that has been incubated with RNA containing one or more transgenes.

## Objects and Advantages

Accordingly, besides the ease and directness by which one may obtain transgenic animals in our above patent, several objects and advantages of the present invention are:

- (a) To provide a means to treat hereditary diseases and cancer;
- (b) to provide episomal transmission of the transgene(s), without disrupting the chromosomal DNA;
- (c) to provide active expression of transgenes in the animal(s);
- (d) to provide replication of the transgenes;
- (e) to provide a means of removing the transgenes from the animals at a later time; and
- (f) to provide a means of marking particular strains of animals to prevent theft of proprietary strains.

Further objects and advantages will become apparent from a consideration of the ensuing description and drawings.

## DRAWING FIGURES

**Fig. 1.** Schematic outline of the procedure for generating animals expressing new genes by means of RNA transfer.

**Fig. 2.** Schematic drawing of the vector VLMB.

**Fig. 3.** Table summarizing the results of polymerase chain reaction (PCR) analysis of cDNA in various tissues of F<sub>0</sub> offspring.

**Fig. 4.** Detailed example of an analysis of PCR testing (two animals).

**Fig. 5.** Table summarizing the results of polymerase chain reaction (PCR) analysis of cDNA in various tissues of F<sub>1</sub> offspring.

## DESCRIPTION—DEFINITIONS

### Definitions

*Reverse transcription:* The process by which ribonucleic acid (RNA) molecules are converted into deoxyribonucleic acid molecules (DNA).

*Retrovirus:* Any of the family of viruses known as *retroviridae*. A characteristic of these viruses is their ability to convert RNA molecules to DNA molecules by means of reverse transcriptase.

**Retrotransposon(s):** Cellular mobile genetic element(s) that replicate by means of the enzyme reverse transcriptase, either by means of a retrotransposon-encoded reverse transcriptase enzyme, or by means of a viral or cellular reverse transcriptase enzyme.

**Retro-vector:** A vector for gene transfer that is derived from a retrovirus or retrotransposon.

**Transfection:** Transfer of RNA or DNA into cells, tissues, or embryos by chemical or physical methods.

**Transduction:** Transfer of RNA or DNA into cells, tissues, or embryos by means of virus particles.

**Founder animal:** The first generation of animal that contains a foreign gene that is transmissible to its progeny.

## DESCRIPTION—FIGS. 1 AND 2—PREFERRED EMBODIMENT

In the invention (Fig 1), the RNA molecules are incubated with and are taken up by the sperm cells, where they are reverse-transcribed into complementary DNA (cDNA) molecules. The sperm cells are used to fertilize oocytes *in vitro*, transferring to the embryos the newly synthesized cDNA. The two-cell embryos are transferred to foster mothers, where they give rise to founder ( $F_0$ ) animals. Analysis of the  $F_0$  animals indicates distribution and expression in different tissues. Through breeding, the cDNA sequences can be transmitted and expressed in subsequent generations of animals.

In a preferred embodiment of the invention, the RNA molecules are derived from a retrovirus, a retrotransposon, or a retro-vector derived from sequences related to retro-elements, such as the exemplary vector VLMB (Fig. 2). Such RNA molecules favor the uptake and conversion of the RNA to linear and circular cDNA molecules that are substrates for potential integration (into genomic DNA) as well as for autonomous replication as episomal DNA molecules.

### Preferred Embodiments of the Invention

**Preferred Embodiment 1:** *In vitro* fertilization (IVF) generation of  $F_0$  founder mice expressing new genetic information using spermatozoa pre-incubated with RNA.

Mouse epididymal sperm cells were surgically obtained from male donor(s) (Hogan, 1994) and incubated with RNA transcribed from retroviral vector pVLMB DNA (Hodgson *et al.*, PCT/US98/24667) bearing the *Lac-z* (beta-galactosidase) reporter gene. Routinely, 50 ng of RNA per  $10^6$  spermatozoa were mixed in fertilization medium (FM, Whittingham, 1971) for 30 min in 5% carbon dioxide in air.  $2 \times 10^6$  sperm cells were then withdrawn from the incubation mixture and used to fertilize oocytes according to published procedure (Hogan, 1994); embryos were grown *in vitro* to the two-cell stage and then implanted into foster mothers. Approximately 30 days after birth, randomly selected offspring were sacrificed, DNA samples were extracted from different organs, and were analyzed by direct PCR using appropriate oligonucleotide primer combinations designed to amplify portions of the *Lac-z* gene (Fig. 3 & 4). The results demonstrated

that: a) cDNA molecules complementary to the sperm-challenging RNA were detected in most of the screened animals; b) the cDNA was distributed non-homogenously within the organs of the same animal, including gonads and gametes; and c) *Lac-z* gene expression was detected by appropriate staining in some of the PCR-positive organs.

**Preferred Embodiment 2:** *Foreign genetic information is transferred from  $F_0$  founders to  $F_1$  progeny.*

Founders were bred with wild type mice generating  $F_1$  progeny. Offspring were preferentially selected from those generated by founders that had PCR-positive gonads and gametes.  $F_1$  animals were sacrificed and the DNA was extracted from various organs and was analyzed by direct PCR amplification as described above (Fig. 5). The results demonstrate that: a) cDNA molecules are transferred from  $F_0$  founders to  $F_1$  progeny via gametes; b) cDNA was detected with variable frequencies in all  $F_1$  animals (at least in the DNA of one organ of each animal); c) the cDNA shows a mosaic distribution within the organs of the same animal; d) some organs, more than others, appear to be preferential targets for cDNA molecules; and e) the *Lac-z* retrogene shows a sharp preferential expression in specific tissues (spleen and lungs).

**Preferred Embodiment 3:** *Foreign genetic information is transferred from targeted tissues of positive mice to 3T3 cell cultures.*

$F_0$  and  $F_1$  mice were sacrificed, organs were collected, and DNA samples were extracted from a small fragment of each organ and used for PCR screening. PCR positive tissues were homogenized in a Potter homogenizer, spun down to sediment cellular debris and the supernatants were collected and filtered through a 0.22  $\mu$ m filter. Aliquots of the supernatants were then incubated with Lipofectamine<sup>™</sup> reagent (Invitrogen Corporation, Bethesda, MD) as described by Hodgson and Solaiman, 1996, *Supra*, and were then added to mouse NIH 3T3 cell cultures and incubated overnight. The following day the supernatant-containing medium was removed and substituted with fresh medium and cells were allowed to grow for one more day. 0.8 mg/ml of G418 were added to plates and cells were incubated for further 5 to 7 days. Control plates, containing cells that had not been incubated with supernatants, as well as those incubated with equivalent supernatants extracted from organs of wild type mice, were also incubated in parallel with the same amounts of G 418. Cells resistant to G418 were selected among the plates treated with supernatants from PCR positive tissues but not from untreated cells or those incubated with extracts from tissues of wild type mice. This result suggested that NIH 3T3 cells acquired G418 resistance through a transduction-like process, and that the foreign genes were transmitted by a retrovirus or a retrovirus-like particle.

**Preferred Embodiment 4:** *Use of RNA to prevent manifestations of hereditary disease*

A retro-vector, such as the exemplary VLMB, above, is adapted by the addition or substitution of a therapeutic gene, for example the cystic fibrosis membrane conductance regulator (CFTR) gene that plays a key role in cystic fibrosis disease (when the gene is defective). The compensatory gene may alternatively be: used alone; substituted for the reporter gene; or fused to the reporter gene. In a preferred embodiment of CFTR gene

therapy, the CFTR gene promoter may be included in the construct, or another promoter, such as a retroviral long terminal repeat promoter, or retrotransposon long terminal repeat promoter (such as a retrotransposon VL30 long terminal repeat promoter) may be used to express the gene. The retro-vector DNA is then introduced into a retrovirus vector producer cell line, and vector RNA is produced and packaged into virions that are released into the cell culture medium. The vector RNA is then harvested from the virions by first concentrating the virus by centrifugation of the cell culture media from vector producer cells, then extracting the RNA from the virus by means of organic solvents. Briefly, for example, the cell culture media is removed from vector producer cells and is filtered through 0.45 micron cellulose acetate filters. The filtered media is then centrifuged, for example at 18,000 RCF for 30 min. to pellet the virus. The virus pellet is resuspended in 1ml of phosphate buffered saline (PBS, Invitrogen Corp., Bethesda, MD), and is extracted with an equal volume of phenol/chloroform/isoamyl alcohol (25:24:1). The aqueous phase is re-extracted twice with chloroform/isoamyl alcohol (24:1), and is precipitated with 1/9<sup>th</sup> volume of sodium acetate, pH 5.6, and three volumes of ethanol.

50ng of the RNA/10<sup>6</sup> sperm cells is then incubated with human sperm cells that have been washed as described in Preferred Embodiment 1, *supra*. The RNA is used to fertilize human eggs, using IVF or artificial insemination, resulting in offspring bearing, transmitting and expressing the transgene (refer to Preferred Embodiment 1 for details, as well as to Preferred embodiments 2 and 3 for additional information about detection and transmission). Expression of the transgene(s) in humans is detected by a method such as sweat chloride analysis, patch clamp studies, antibody detection, etc. Alternatively, the fusion reporter-therapeutic gene expression is observed by means of detection of the reporter gene.

Because the therapeutic gene is inserted episomally, it does not permanently alter the germ line. However, three caveats of human embryonic gene therapy are: 1) that the transgene might be regulated abnormally, requiring its removal; or 2) it might become integrated, requiring its removal at a later time; or 3) a better therapy (such as direct gene repair) may become available in the, requiring removal of the transgene. In any event, these exigencies may be addressed by including within the vector a so-called suicide gene, such as the herpes simplex virus thymidine kinase (TK) gene. The method of S. Freeman *et al.*, (Cancer therapy utilizing malignant cells expressing HSV-TK, 1997, US Patent No. 5,601,818) can be used, and is incorporated herein as if fully set forth. Treatment of the human with a non-toxic pro-drug, such as gancyclovir, is used to eliminate cells expressing the transgene.

Although the description above contains many specificities, these should not be construed as limiting the scope of the invention but as merely providing illustrations of some of the presently preferred embodiments of this invention. Thus, the scope of the invention should be determined by the appended claims and their legal equivalents, rather than by the examples given.